Outbreak: Lessons from Ebola. On 6 December 2013 a two-year-old boy called Emile Ouamouno died of a serious illness in a small village in Guinea. A month later Emile’s three-year-old sister, his mother and grandmother were all dead. This was the start of an Ebola epidemic that swept through West Africa in 2014, killing over 11,000 people and infecting nearly 30,000.
An interdisciplinary team of Oxford University researchers has devised a new technique to speed up the development of novel vaccines.
Applications are now open for the prestigious Wellcome Trust funded 4 year PhD programme in Infection, Immunology and Translational Medicine.
5th to 9th October 2015, Bamako, Mali. Following the success of the first two “Vaccinology in Africa” courses held in Accra, Ghana (September 2013), and Nairobi Kenya (October 2014), this year’s annual course will be joint hosted by the Malaria Research and Training Centre (MRTC), Bamako Mali and ...
Just published - the report covers a summary of progress across the Institute's portfolio of research programmes and update on latest activities.
The Institute has expanded substantially in the last 10 years with several enlarging groups, strategic recruitments and a broadening base of funders from four continents. Recently, the Institute’s capacity to undertake small scale first-in-human trials very rapidly was illustrated by the request from the World Health Organization to undertake, with collaborators, the first trial of a new Ebola vaccine destined for West Africa in the 2014 outbreak.
A clinical trial to evaluate an Ebola vaccine has begun in Dakar, Senegal, after initial research started at the Jenner Institute, Oxford University. The first volunteers of the trial at Centre Hospitalier Universitaire le Dantec in Dakar received an initial vaccination at the start of July, with a booster vaccination one week later. While this is a short timescale for immunisation, if proved successful it would provide an option to respond to an Ebola outbreak with a rapid vaccination programme.
LONDON, June 15 (Reuters) - Three years after the mysterious MERS virus first emerged in humans, scientists and drugmakers say there is no excuse for not having a vaccine that could have protected those now falling sick and dying in South Korea. "The question is: How long are we going to wait around and just follow these outbreaks before we get serious about making vaccines?" said Adrian Hill, a professor and director at the Jenner Institute at Britain's Oxford University.
If you have news or events that you would like to be added to this website, please email us details. If possible, please include a picture and links to further information.